Morgan Stanley: Maintains "Overweight" rating on AKESO (09926) with target price raised to HK$78.

Morgan Stanley released a research report stating that it maintains a "buy" rating for AKESO (09926) and has raised the target price from HK$64 to HK$78. The data from the HARMONi-2 trial far exceeded expectations, and due to the strong data from HARMONi-2 and the consistency in safety, the company's revenue model has been adjusted to reflect overseas revenue contributions. The company's loss forecast for this year has been revised down by 30%, next year's loss forecast by 17%, and the profit forecast for 2026 has been raised by 13%.